

FOR HEALTHCARE PROFESSIONALS ONLY

The European Society of Cataract and Refractive Surgeons (ESCRS) Congress 2022

Monday 19th September 2022, Space 4, Level 0,
MiCo (Milano Convention Centre)

New XEN63[®], an ab interno gel implant, as a solo procedure or in
combination with phacoemulsification in primary open-angle glaucoma

13:00–13:02 CEST	Welcome and Introduction	Roberto Carassa, MD (Italy)
13:02–13:17 CEST	XEN63 [®] – New dimensions in ab interno micro-incisional glaucoma surgery	Ike Ahmed, MD (Canada)
13:17–13:55 CEST	Clinical cases session:*	
	13:17–13:36 New XEN63 [®] Implant in Primary Open-Angle Glaucoma Patients	Antonio Fea, MD (Italy)
	13:36–13:55 New XEN63 [®] Implant in Primary Open-Angle Glaucoma Patients in combination with cataract surgery	Michele Figus, MD (Italy)
13:55–14:00 CEST	Wrap up and close	Roberto Carassa, MD (Italy)

* POAG Clinical cases & Discussion session between speakers and moderated
by Chair (9 min presentation + 10 min discussion), including voting system
during the presentation of the cases

Presenters are consultants to Allergan, an AbbVie Company. Organised and funded by Allergan, an AbbVie Company. This symposium
for healthcare professionals contains promotional material. The symposium is in relation to AbbVie products.

Materials developed in accordance with CE mark. Registration conditions and licenses differ internationally, please refer to your local
directions for use (DFU). A list of countries with this product/ indication is available from ukmedinfo@abbvie.com.

**The XEN[®] Gel implant is intended to reduce intraocular pressure in patients with primary open angle glaucoma where previous
medical treatments have failed.** Materials developed under C.E. product license 2797. XEN[®] is a class III Medical Device. Medical
devices have associated risks, please refer to the contraindications and warnings sections in the Directions For Use.

Adverse events should be reported to your Ministry of Health and local AbbVie office. XEN63[®]
is expected to be available in Western Europe from September 2022



Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPVP@abbvie.com